Economic Impact

Chronic Overlapping Pain Conditions (COPCs) come at a high cost – to individuals affected by them and their loved ones, our health care system, payers and the U.S. economy at large. Each of the conditions have published cost studies, estimating their impact on our nation’s health and economy. However, one cannot simply total these figures to determine their cumulative cost, as there is substantial overlap among conditions. One of CPRA’s legislative and research priorities is to advance epidemiological studies on the shared prevalence of COPCs and the economic impact of having multiple conditions on individuals, health care systems, payers and the U.S. economy.

Studies have provided the following estimates of the annual U.S. economic impact of COPCs:

• Vulvodynia:                                                                                                  $31-72 billion
• Temporomandibular Disorders:                                                                    $32 billion    
• Myalgic Encephalomyelitis / Chronic Fatigue Syndrome:                          $32 billion
• Irritable Bowel Syndrome:                                                                            $380 billion
• Interstitial Cystitis / Painful Bladder Syndrome:                                         $22 billion
• Fibromyalgia                                                                                                     $20 billion
• Endometriosis                                                                                                  $22 billion
• Migraine                                                                                                            $17 billion
• Chronic Tension-Type Headache                                                                    unknown
• Chronic Low Back Pain                                                           $100 billion (“low back pain")

   

   

  Learn about symptoms & prevalence data on copcs  ▸